Improving Diagnosis and Care for Patients With Sarcoma: Do Real-World General Practitioners Data and Prospective Data Collections Have a Place Next to Clinical Trials?
Authors:
- Emily I. HolthuisEHEmily I. Holthuis
- Marianne J. HeinsMHMarianne J. Heins
- Rick L. HaasRick L. Haas
- Jetty A. OverbeekJOJetty A. Overbeek
- Tim C. Olde HartmanTHTim C. Olde Hartman
- Annemarie A. UijenAUAnnemarie A. Uijen
- Leonard WeeLWLeonard Wee
- Winette T.A. van der GraafWinette T.A. van der Graaf
- Olga HussonOHOlga Husson
- 1 June 2024
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 8 (8) , e2400054
Abstract
There has been growing interest in the use of real-world data (RWD) to address clinically and policy-relevant (research) questions that cannot be answered with data from randomized controlled trials (RCTs) alone. This is, for example, the case in rare malignancies such as sarcomas as limited patient numbers pose challenges in conducting RCTs within feasible timeliness, a manageable number of collaborators, and statistical power. This narrative review explores the potential of RWD to generate real-world evidence (RWE) in sarcoma research, elucidating its application across different phases of the patient journey, from prediagnosis to the follow-up/survivorship phase. For instance, examining electronic health records (EHRs) from general practitioners (GPs) enables the exploration of consultation frequency and presenting symptoms in primary care before a sarcoma diagnosis. In addition, alternative study designs that integrate RWD with well-designed observational RCTs may offer relevant information on the effectiveness of clinical treatments. As, especially in cases of ultrarare sarcomas, it can be an extreme challenge to perform well-powered randomized prospective studies. Therefore, it is crucial to support the adaptation of novel study designs. Regarding the follow-up/survivorship phase, examining EHR from primary and secondary care can provide valuable insights into identifying the short- and long-term effects of treatment over an extended follow-up period. The utilization of RWD also comes with several challenges, including issues related to data quality and privacy, as described in this study. Notwithstanding these challenges, this study underscores the potential of RWD to bridge, at least partially, gaps between evidence and practice and holds promise in contributing to the improvement of sarcoma care.Keywords
This publication has 65 references indexed in Scilit:
- Patient-Reported Outcomes, Tumor Markers, and Survival Outcomes in Advanced GI CancerJAMA Network Open, 2023
- The Current Landscape and Emerging Applications for Real‐World Data in Diagnostics and Clinical Decision Support and its Impact on Regulatory Decision MakingClinical Pharmacology & Therapeutics, 2022
- Overall and net survival of patients with sarcoma between 2005 and 2010: Results from the French Network of Cancer Registries (FRANCIM)Cancer, 2022
- Ultra‐rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entitiesCancer, 2021
- Patient and diagnostic intervals of survivors of sarcoma: Results from the SURVSARC studyCancer, 2020
- Radiomics approach to distinguish between well differentiated liposarcomas and lipomas on MRIBritish Journal of Surgery, 2019
- The opportunities and shortcomings of using big data and national databases for sarcoma researchCancer, 2019
- Real‐World Data for Regulatory Decision Making: Challenges and Possible Solutions for EuropeClinical Pharmacology & Therapeutics, 2019
- Assessment of the Accuracy of Disease Coding Among Patients Diagnosed With SarcomaJAMA Oncology, 2018
- Treatment late effects in long‐term survivors of pediatric sarcomaPediatric Blood & Cancer, 2006